These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37985979)

  • 1. Evaluation of a person-centred, nurse-led model of care delivering hepatitis C testing and treatment in priority settings: a mixed-methods evaluation of the Tasmanian Eliminate Hepatitis C Australia Outreach Project, 2020-2022.
    Dawe J; Hughes M; Christensen S; Walsh L; Richmond JA; Pedrana A; Wilkinson AL; Owen L; Doyle JS;
    BMC Public Health; 2023 Nov; 23(1):2289. PubMed ID: 37985979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating people where they are: Nurse-led micro-elimination of hepatitis C in supported housing sites for networks of people who inject drugs in Victoria, Canada.
    Selfridge M; Barnett T; Lundgren K; Guarasci K; Milne R; Drost A; Fraser C
    Public Health Nurs; 2022 Sep; 39(5):1009-1016. PubMed ID: 35537120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a Project Integrating Financial Incentives into a Hepatitis C Testing and Treatment Model of Care at a Sexual Health Service in Cairns, Australia, 2020-2021.
    Dawe J; Gorton C; Lewis R; Richmond JA; Wilkinson AL; Pedrana A; Stoové M; Doyle JS; Russell D
    Viruses; 2024 May; 16(5):. PubMed ID: 38793681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia.
    Harney BL; Whitton B; Paige E; Brereton R; Weiss R; Membrey D; Wade AJ; Iser D; Kemp W; Roberts SK; Spelman T; Sacks-Davis R; Hellard ME; Doyle JS
    Liver Int; 2022 Mar; 42(3):522-531. PubMed ID: 34821021
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Byrne C; Radley A; Inglis SK; Beer LJZ; Palmer N; Pham MD; Healy B; Doyle JS; Donnan P; Dillon JF
    BMJ Open; 2020 Aug; 10(8):e036501. PubMed ID: 32868356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility.
    MacIsaac MB; Whitton B; Hubble A; Cogger S; Penn M; Weeks A; Elmore K; Pemberton D; Anderson J; Howard R; McKeever U; Papaluca T; Hellard ME; Stoove M; Wilson D; Pedrana A; Doyle J; Clark N; Holmes J; Thompson AJ
    Med J Aust; 2023 Apr; 218(6):256-261. PubMed ID: 36919230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engaging people who inject drugs in hepatitis C virus testing and prevention through community-based outreach, in Sydney, Australia.
    Coupland H; White B; Bates A; Park JN; Iversen J; Maher L
    Drug Alcohol Rev; 2019 Feb; 38(2):177-184. PubMed ID: 30652363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care.
    Papaluca T; McDonald L; Craigie A; Gibson A; Desmond P; Wong D; Winter R; Scott N; Howell J; Doyle J; Pedrana A; Lloyd A; Stoove M; Hellard M; Iser D; Thompson A
    J Hepatol; 2019 May; 70(5):839-846. PubMed ID: 30654067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of the CT2 study: A 'one-stop-shop' for community-based hepatitis C testing and treatment in Yangon, Myanmar.
    Draper BL; Htay H; Pedrana A; Yee WL; Howell J; Pyone Kyi K; Naing W; Sanda Aung K; Markby J; Easterbrook P; Bowring A; Aung W; Sein YY; Nwe N; Myint KT; Shilton S; Hellard M
    Liver Int; 2021 Nov; 41(11):2578-2589. PubMed ID: 34153155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C treatment in a co-located mental health and alcohol and drug service using a nurse-led model of care.
    Harney BL; Brereton R; Whitton B; Pietrzak D; Paige E; Roberts SK; Birks S; Saraf S; Hellard ME; Doyle JS
    J Viral Hepat; 2021 May; 28(5):771-778. PubMed ID: 33599036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study.
    Williams B; Howell J; Doyle J; Thompson AJ; Draper B; Layton C; Latham N; Bramwell F; Membrey D; Mcpherson M; Roney J; Stoové M; Hellard ME; Pedrana A
    Int J Drug Policy; 2019 Oct; 72():91-98. PubMed ID: 31129023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system.
    Gibbs D; Price O; Grebely J; Larney S; Sutherland R; Read P; Butler K; Degenhardt L; Peacock A
    Drug Alcohol Depend; 2021 Nov; 228():109050. PubMed ID: 34607193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia.
    Iversen J; Grebely J; Catlett B; Cunningham P; Dore GJ; Maher L
    Int J Drug Policy; 2017 Sep; 47():77-85. PubMed ID: 28578863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.
    Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L
    Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
    Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
    J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service.
    Wade AJ; Macdonald DM; Doyle JS; Gordon A; Roberts SK; Thompson AJ; Hellard ME
    PLoS One; 2015; 10(11):e0142770. PubMed ID: 26562516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study.
    Howell J; Traeger MW; Williams B; Layton C; Doyle JS; Latham N; Draper B; Bramwell F; Membrey D; McPherson M; Roney J; Stoové M; Thompson AJ; Hellard ME; Pedrana A
    J Viral Hepat; 2022 May; 29(5):375-384. PubMed ID: 35274403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial.
    Byrne CJ; Radley A; Inglis SK; Beer L; Palmer N; Duc Pham M; Allardice K; Wang H; Robinson E; Hermansson M; Semizarov D; Healy B; Doyle JS; Dillon JF
    Aliment Pharmacol Ther; 2022 Jun; 55(12):1512-1523. PubMed ID: 35538396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
    Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P
    Int J Drug Policy; 2023 Apr; 114():103982. PubMed ID: 36863287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
    Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
    Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.